Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

James M. Cleary

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7213-3951; OpenAlex author ID A5018655814. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 0, last author 5)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
119
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper, 1 trial · 2019: none · 2020: none · 2021: 3 papers · 2022: 2 papers, 2 trials · 2023: 6 papers · 2024: 4 papers · 2025: 2 papers · 2026: 7 papers

Papers 26

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  4. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Last author DOI 10.1158/1078-0432.ccr-24-3766↗
  5. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  6. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  7. Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer Co-author DOI 10.64898/2026.09.24.754062↗
  8. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Co-author DOI 10.1126/science.adk3487↗
  9. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  10. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  11. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  12. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  13. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  14. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Last author DOI 10.1001/jamanetworkopen.2022.49720↗
  15. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  16. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  17. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  18. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  19. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Last author DOI 10.1158/1078-0432.ccr-23-2005↗
  20. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  21. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers14246223↗
  22. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  23. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  24. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Last author DOI 10.21037/jgo-21-197↗
  25. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  26. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1634/theoncologist.2014-0086↗

Trials 3

  1. Adavosertib and Gemcitabine in Advanced Pancreatic Principal investigator NCT05212025↗
  2. Switch Maintenance in Pancreatic Principal investigator NCT05419479↗
  3. Niraparib in Patients With Pancreatic Cancer Principal investigator NCT03601923↗

Closest collaborators

The 25 strongest of 119 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 22 shared papers, 2014–2026 · strength 3.11
  2. Andrew J. Aguirre · 18 shared papers, 2021–2026 · strength 2.64
  3. Kimberly J. Perez · 16 shared papers, 2021–2026 · strength 2.31
  4. Harshabad Singh · 15 shared papers, 2021–2026 · strength 2.23
  5. Douglas Adam Rubinson · 16 shared papers, 2014–2026 · strength 2.15
  6. Jonathan Andrew Nowak · 13 shared papers, 2021–2026 · strength 1.92
  7. Brandon M. Huffman · 11 shared papers, 2021–2026 · strength 1.73
  8. Srivatsan Raghavan · 12 shared papers, 2021–2026 · strength 1.69
  9. Matthew B.B. Yurgelun · 7 shared papers, 2021–2026 · strength 1.03
  10. Kimmie Ng · 8 shared papers, 2014–2026 · strength 0.99
  11. Andressa Dias Costa · 7 shared papers, 2021–2026 · strength 0.95
  12. Joseph Douglas Mancias · 6 shared papers, 2022–2026 · strength 0.94
  13. Thomas Adam Abrams · 6 shared papers, 2023–2026 · strength 0.91
  14. Stephanie K. Dougan · 6 shared papers, 2021–2026 · strength 0.90
  15. Rishi Surana · 6 shared papers, 2022–2026 · strength 0.89
  16. Thomas E. Clancy · 6 shared papers, 2021–2026 · strength 0.80
  17. Geoffrey Ira Shapiro · 6 shared papers, 2021–2026 · strength 0.76
  18. Hannah L. Williams · 5 shared papers, 2021–2025 · strength 0.61
  19. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.60
  20. Alan D. D’Andrea · 4 shared papers, 2021–2026 · strength 0.56
  21. ANDREA C Enzinger · 3 shared papers, 2025–2026 · strength 0.52
  22. Michael Lawrence Dougan · 3 shared papers, 2024–2026 · strength 0.51
  23. Chen Yuan · 4 shared papers, 2022–2024 · strength 0.50
  24. Colin D. Weekes · 3 shared papers, 2023–2026 · strength 0.47
  25. William A. Freed-Pastor · 3 shared papers, 2022–2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.